Učitavanje...
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy individuals. After a bout of acute gastroenteritis, postinfection IBS may result in up to approximately 10% of those...
Spremljeno u:
| Izdano u: | Therap Adv Gastroenterol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6984424/ https://ncbi.nlm.nih.gov/pubmed/32047534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284819897531 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|